ArticleOncoimmunology
Harnessing innate lung anti-cancer effector functions with a novel bacterial-derived immunotherapy.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05677113 (A Phase II Study of Perioperative QBECO Site Specific Immunomodulator), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Study of Perioperative QBECO Site Specific Immunomodulator (Qu Biologics®) in Patients With Metastatic Colorectal Adenocarcinoma Within the Liver Undergoing Resection
Who cites it
8 citing papers in PubMed, 18 citations in OpenAlex.
- Immune Stimulation Using a Gut Microbe-Based Immunotherapy Reduces Disease Pathology and Improves Barrier Function in Ulcerative Colitis.Frontiers in immunology · 2018Trial
- Intratumoral Microbiota in Lung Cancer: Emerging Roles in TME Modulation and Immunotherapy Response.International journal of molecular sciences · 2025Review
- Hacking the Immune Response to Solid Tumors: Harnessing the Anti-Cancer Capacities of Oncolytic Bacteria.Pharmaceutics · 2023Review
- Current advances in microbial-based cancer therapies.Medical oncology (Northwood, London, England) · 2023Review
- Immunotherapy: A new target for cancer cure (Review).Oncology reports · 2023Review
- Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers - a retrospective study of a single institution.Cancer immunology, immunotherapy : CII · 2021Article
- Therapeutic vaccination immunomodulation: forming the basis of all cancer immunotherapy.Therapeutic advances in vaccines and immunotherapy · 2019Review
- White paper on microbial anti-cancer therapy and prevention.Journal for immunotherapy of cancer · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 2 countries.
Funding
Abstract
Acute infection is known to induce strong anti-tumor immune responses, but clinical translation has been hindered by the lack of an effective strategy to safely and consistently provoke a therapeutic response. These limitations are overcome with a novel treatment approach involving repeated subcutaneous delivery of a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.